文献速递血栓与止血

重组凝血因子IX Fc融合蛋白在B型血友病中的疗效与安全性的纵向事后评估

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
PubMed 文献 · Blood Adv · 2023-01-01

该研究事后汇总分析B-LONG、Kids B-LONG及B-YOND研究中接受rFIXFc预防治疗的123例和30例重型B型血友病患者纵向数据至6.5年,发现年化出血率持续低、因子消耗稳定、依从性高,基线靶关节完全消退且90.2%无复发。

要点

  • rFIXFc预防治疗在重型B型血友病患者中年化出血率持续低、因子消耗稳定、依从性高。
  • 给药间隔≥14天或基线存在靶关节者仍维持低年化出血率。
  • 可评估靶关节完全消退,随访期间90.2%基线靶关节无复发。

核心结论

  • rFIXFc预防治疗与持续临床获益相关,包括长期出血预防和靶关节消退,适用于重型B型血友病。

研究设计与样本

  • 事后汇总分析B-LONG(NCT01027364)和Kids B-LONG(NCT01440946)两项3期试验及长期扩展研究B-YOND(NCT01425723)的纵向数据,最长6.5年。
  • B-LONG纳入123例≥12岁患者,Kids B-LONG纳入30例<12岁患者,其中分别有93例和27例进入B-YOND。
  • B-LONG中≥12岁患者接受每周剂量调整预防(起始50 IU/kg)、个体化间隔调整预防(初始100 IU/kg每10天)或按需治疗;Kids B-LONG中<12岁患者接受50-60 IU/kg每7天并按需调整。
  • B-YOND中患者接受每周预防(20-100 IU/kg每7天)、间隔调整预防(100 IU/kg每8-16天)、改良预防或按需治疗,允许组间切换。
  • B-LONG/B-YOND组中位累积治疗时长3.63年(范围0.003-6.48年),Kids B-LONG/B-YOND组2.88年(范围0.30-4.80年)。

主要发现

  • 整个治疗期间年化出血率保持低水平,年化因子消耗保持稳定,依从性保持高。
  • 给药间隔≥14天或基线存在靶关节的患者也维持低年化出血率。
  • 可评估靶关节完全消退,随访期间90.2%的基线靶关节无复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3 trials (B-LONG [#NCT01027364] and Kids B-LONG [#NCT01440946]) and a long-term extension study (B-YOND [#NCT01425723]). In this study, we report post hoc analyses of pooled longitudinal data for up to 6.5 years for rFIXFc prophylaxis. In the B-LONG study, subjects ≥12 years received weekly dose-adjusted prophylaxis (WP; starting dose, 50 IU/kg), individualized interval-adjusted prophylaxis (IP; initially, 100 IU/kg every 10 days), or on-demand dosing. In the Kids B-LONG study, subjects <12 years received 50 to 60 IU/kg every 7 days, adjusted as needed. In the B-YOND study, subjects received WP (20-100 IU/kg every 7 days), IP (100 IU/kg every 8-16 days), modified prophylaxis, or on-demand dosing; switching between treatment groups was permitted. A total of 123 subjects from B-LONG and 30 from Kids B-LONG study were included, of whom 93 and 27, respectively, enrolled in the B-YOND study. The median cumulative duration of treatment was 3.63 years (range, 0.003-6.48 years) in B-LONG/B-YOND and 2.88 years (range, 0.30-4.80 years) in Kids B-LONG/B-YOND group. Annualized bleed rates (ABRs) remained low, annualized factor consumption remained stable, and adherence remained high throughout treatment. Low ABRs were also maintained in subjects with dosing intervals ≥14 days or with target joints at baseline. Complete resolution of evaluable target joints and no recurrence in 90.2% of baseline target joints during follow-up were observed. rFIXFc prophylaxis was associated with sustained clinical benefits, including long-term bleed prevention and target joint resolution, for severe hemophilia B.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shapiro AD, Kulkarni R, Ragni MV, et al. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023. PMID: 36848635. doi:10.1182/bloodadvances.2022009230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。